South African doctors are raising alarm bells as the investigational weight-loss drug retatrutide begins circulating through unregulated channels, months ahead of any regulatory approval. The warning, reported by Eyewitness News (EWN) on July 14, 2026, highlights the growing global challenge of unauthorized access to experimental obesity treatments.
Dr. Tracy Nelwamondo, a general practitioner specializing in doctor-led weight management, told EWN that patients are obtaining and self-administering retatrutide despite the drug remaining in clinical trials. “The problem that we face now is that it is not the right time. The medicine has just gone through its phase three trials. If you are not enrolled, you are not supposed to be using it,” she said.
Retatrutide, Eli Lilly’s triple agonist targeting GLP-1, GIP, and glucagon receptors, made headlines in May 2026 when Phase 3 TRIUMPH-1 trial results showed weight loss of up to 30.3% — on par with bariatric surgery. The drug is expected to receive regulatory approval from agencies such as the U.S. FDA and the European Medicines Agency as early as 2027, but it is not yet approved for commercial sale anywhere in the world.
Despite this, a recent investigation by South Africa’s Mail and Guardian found that retatrutide is already being promoted on social media platforms, in wellness spaces, and even in gyms. Buyers may have no way of knowing what they are actually injecting, Dr. Nelwamondo cautioned. “We don’t know how the medicines interact with the human body. We need guidance. We need to know how the medicines work, how they interact with other medicines that a person can be taking.”
The situation mirrors concerns raised by other health authorities. The U.S. Food and Drug Administration (FDA) and Health Canada have both issued warnings about compounded and counterfeit GLP-1 drugs, including semaglutide and tirzepatide, flooding online marketplaces. Retatrutide’s remarkable efficacy data has made it an attractive target for counterfeiters looking to capitalize on demand before legitimate supply chains are established.
Canadian Context
The South African experience carries direct lessons for Canadians. Retatrutide is not approved by Health Canada, and no legitimate supply exists in the country. Yet Canadian consumers are equally susceptible to online vendors offering “generic” or “research-grade” retatrutide through unregulated websites and social media channels.
Canada has already seen cases of liver injury linked to unlicensed semaglutide products obtained online, as reported by Health Canada and provincial authorities. With retatrutide generating even greater public interest following its Phase 3 results, the risk of Canadians seeking out unauthorized sources is significant.
Health Canada advises that any weight-loss drug purchased without a prescription from an unlicensed online pharmacy carries unknown risks: incorrect dosage, contamination, substitution with dangerous substances, and lack of medical oversight. Canadians should only access retatrutide through legitimate clinical trials (listed on ClinicalTrials.gov) and should never purchase it from unregulated vendors, regardless of how convincing the marketing appears.
For those interested in retatrutide, the only safe path forward is to wait for Health Canada approval, which is anticipated following FDA and EMA decisions likely in 2027. In the meantime, Canadians should consult with their healthcare providers about approved and medically supervised obesity treatment options.
Sources
- EWN: SA doctors caution against use of unauthorised weight-loss drug retatrutide (July 14, 2026)
- Mail and Guardian: Illegal weight-loss drug floods SA (July 2, 2026)
- Health Canada: Unauthorized health products — Risks of buying drugs online